search

Active clinical trials for "Sinus Thrombosis, Intracranial"

Results 1-10 of 17

The Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus...

Cerebral Venous Sinus Thrombosis

A prospective, single-center, open-label,randomized, controlled,non-inferiority clinical trial will be conducted to evaluate the safety and efficacy of a dedicated venous sinus thrombectomy stent for endovascular treatment of cerebral venous sinus thrombosis.

Recruiting13 enrollment criteria

Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache

Stroke (CVA) or TIAHeadache8 more

Post stroke headache occurs in approximately 10-23% of all stroke patients. Its onset is shortly after experiencing a stroke, or stroke like event, and persists for at least three months. These headaches have features which resemble migraine or occur in people who have a previous history of migraine that was once infrequent. Botox is a treatment that is currently approved for the treatment of chronic migraine, that is migraine headaches occurring for at least 15 days a month for at least 3 months. Given the clinical similarity in character and frequency of post stroke headache and migraine, and the fact that stroke affects structures like the blood vessels in the brain that are also affected in migraine, this study is to investigate the possible role that Botox would have in the treatment of Post-Stroke Headache.

Not yet recruiting10 enrollment criteria

Anatomical Variation of Cerebral Venous Sinus in Healthy Individuals

Venous Sinus ThrombosisCranial

The anatomical characteristics of veins and venous sinus result in great differences between cerebral venous system diseases and cerebral artery diseases in etiology, pathophysiology and clinical features.Therefore, understanding the anatomy and variation of normal venous sinuses is essential to identify the intracranial venous lesions.

Recruiting8 enrollment criteria

The Norwegian Cerebral Venous Thrombosis Study

Cerebral Vein ThrombosisCerebral Venous Sinus Thrombosis

The NoCVT study will investigate CVT (2010-2019) in a large Norwegian population (> 3 millions) using several approaches combining existing health registries, clinical databases and new prospectively collected clinical data to explore epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of CVT.

Recruiting2 enrollment criteria

Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)

Cerebral Vein ThrombosisCerebral Venous Sinus Thrombosis

This study will investigate the epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of cerebral venous thrombosis in China.

Recruiting2 enrollment criteria

Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis

Sinus ThrombosisIntracranial

Background: Endovascular thrombolysis, with or without mechanical clot removal (ET), may be beneficial for a subgroup of patients with cerebral venous sinus thrombosis (CVT), who have a poor prognosis despite treatment with heparin. Published experience with ET is promising, but only based on case series and not on controlled trials. Objective: The main objective of the TO-ACT trial is to determine if ET improves the functional outcome of patients with a severe form of CVT Study design: The TO-ACT trial will be designed as a multi-centre, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Study population: Patients are eligible if they have a radiologically proven CVT, a high probability of poor outcome (defined by presence of one or more of the following risk factors: mental status disorder, coma, intracranial hemorrhagic lesion or thrombosis of the deep cerebral venous system) and the responsible physician is uncertain if ET or standard anti-coagulant treatment is better. Intervention: Patients will be randomized to receive either ET or standard therapy (therapeutic doses of heparin). ET consists of local application of alteplase or urokinase within the thrombosed sinuses, and/or mechanical thrombectomy. Glasgow coma score, NIH stroke scale and relevant laboratory parameters will be assessed at baseline. Endpoints: The primary endpoint is the modified Rankin scale (mRS) at 12 months. The most important secondary outcomes are the mRS, mortality and recanalization rate at 6 months. Major intra- and extracranial hemorrhagic complications within one week following the intervention are the principal safety outcome. Results will be analyzed according to the "intention-to-treat" principle. Assessment of study endpoints will be carried out according to standardized questionnaires by a blinded neurologist or research nurse who is not involved in the treatment of the patient. Study size: To detect a 50% relative reduction in mRS≥2 (from 40 to 20%), 164 patients (82 in each treatment arm) have to be included (two-sided alpha, 80% power). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Included patients may benefit directly from ET. Complications of ET, most notably intracranial hemorrhages, constitute the most important risk of the study.

Terminated27 enrollment criteria

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients...

Thromboembolism

This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted warfarin on a net clinical benefit endpoint of major bleeding (ISTH criteria) and new venous thrombotic event (VTE) (primary endpoint) with blinded endpoint adjudication.

Completed14 enrollment criteria

Cerebral Venous Thrombosis Cohort Study in China Mainland

Cerebral Venous Sinus ThrombosisDeep Cerebral Vein Thrombosis1 more

This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.

Not yet recruiting2 enrollment criteria

Venous Sinus Thrombosis : Clinical Picture and Outcome

Cerebral Vein Thrombosis

Cerebral venous sinus thrombosis (cvst) is an underdiagnosed neurological condition with variable clinical presentations and variable risk factors CVST is often an underdiagnosed cause of acute or slowly progressive neurological deficit. With increasing awareness of the entity and easy accessibility to the non-invasive test like CT and MRI scans,CVST cases are now being diagnosed more frequently and it is now thought to occur more commonly than previously assumed.it is also probably true that this condition is more frequent in underdeveloped countries

Not yet recruiting4 enrollment criteria

The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis...

Cerebral Venous Sinus ThrombosisBatroxobin

Our previous clinical case observations showed that batroxobin combined with anticoagulation therapy can improve the sinus recanalization rate in patients with CVST, shorten the hospital stay, and increase the neurological score of patients. Its main mechanism is to inhibit thrombosis after reducing fibrinogen, and to dissolve thrombus. To further explore the safety of batroxobin combined with anticoagulation therapy for CVST, an open-label, randomized controlled (1: 1), single-center, prospective study was used. Further study on the safety and effectiveness of batroxobin combined with anticoagulation for CVST.

Unknown status20 enrollment criteria
12

Need Help? Contact our team!


We'll reach out to this number within 24 hrs